| Dimension | Scoring Notes | Score |
|---|---|---|
| Study Design | Multiple human RCTs demonstrating GH stimulation and body composition effects. FDA was previously approved (Geref). Studies range from pediatric GH deficiency to adult anti-aging applications. |
20 / 25 |
| Sample Size | Individual trials typically 30-80 participants. Sermorelin research spans decades but no mega-trial equivalent. Cumulative sample size moderate. |
12 / 20 |
| Replication | Replicated across multiple independent groups — US, European, and academic medical centers. Consistent GH-stimulating effect is well replicated. Body composition outcomes less so. |
15 / 20 |
| Journal Impact Factor | Publications in Journal of Clinical Endocrinology & Metabolism (IF ~6.5), Growth Hormone & IGF Research (IF ~2-3), and Endocrinology. Mix of good and mid-tier journals. |
8 / 15 |
| Funding Independence | Mix of academic/NIH funded studies and some industry support. More independent research than typical peptide compounds. |
4 / 10 |
| Population Diversity | Studied in children with GH deficiency and in adults (mostly middle-aged white males in body composition studies). Limited ethnic diversity in published literature. |
3 / 5 |
| Researcher h-Index | Primary researchers include investigators from academic medical centers with moderate h-Indexes (10-19 range). Not superstar researchers but credible academics. |
2 / 5 |